News & Updates

Rituximab shows promise in management of neuropsychiatric SLE
Rituximab shows promise in management of neuropsychiatric SLE
02 Jul 2024 byStephen Padilla

Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.

Rituximab shows promise in management of neuropsychiatric SLE
02 Jul 2024
Cognitive remediation delivers sustained improvement in schizophrenia
Cognitive remediation delivers sustained improvement in schizophrenia
30 Jun 2024

People with schizophrenia may benefit from cognitive remediation which offers durable improvements in both cognition and psychosocial functioning, as shown in a study.

Cognitive remediation delivers sustained improvement in schizophrenia
30 Jun 2024
High cognitive reserve may counter dementia risk
High cognitive reserve may counter dementia risk
07 Jun 2024